Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos ROVI Rule of 40

The Rule of 40 of Laboratorios Farmaceuticos ROVI (ROVI.MC) as of Nov 15, 2026 is 20.63 %. In the previous year, Rule of 40 was 15.58 % — a change of 32.44% (higher).

Rule of 40

20.63 %

YoY

32.44%

Last updated:

Rule of 40 of Laboratorios Farmaceuticos ROVI is 2025 20.63 % . Rule of 40 of Laboratorios Farmaceuticos ROVI was 2024 15.58 % . It decreases by 32.44% higher compared to the previous year.

The Laboratorios Farmaceuticos ROVI Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
15.75 EUR
Jan 1, 2019
37.00 EUR
Jan 1, 2020
27.92 EUR
Jan 1, 2021
82.45 EUR
Jan 1, 2022
57.35 EUR
Jan 1, 2023
28.00 EUR
Jan 1, 2024
15.58 EUR
Jan 1, 2025
20.63 EUR
The Laboratorios Farmaceuticos ROVI Rule of 40 history
YEARRule of 40YoY
20.63 %+32.44%
15.58 %-44.35%
28.00 %-51.18%
57.35 %-30.45%
82.45 %+195.33%
27.92 %-24.54%
37.00 %+134.85%
15.75 %+45.20%
10.85 %-41.23%
18.46 %+51.02%
12.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorios Farmaceuticos ROVI Stock analysis

What does Laboratorios Farmaceuticos ROVI do? Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorios Farmaceuticos ROVI stock

Rule of 40 of Laboratorios Farmaceuticos ROVI is 20.63 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Laboratorios Farmaceuticos ROVI since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Laboratorios Farmaceuticos ROVI

All Key Metrics — Laboratorios Farmaceuticos ROVI